| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3191 | 2013 |
| Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SM Lippman, EA Klein, PJ Goodman, MS Lucia, IM Thompson, LG Ford, ... Jama 301 (1), 39-51, 2009 | 2752 | 2009 |
| Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer MR Posner, DM Hershock, CR Blajman, E Mickiewicz, E Winquist, ... New England Journal of Medicine 357 (17), 1705-1715, 2007 | 2056 | 2007 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1216 | 2021 |
| Exemestane for breast-cancer prevention in postmenopausal women PE Goss, JN Ingle, JE Alés-Martínez, AM Cheung, RT Chlebowski, ... New England Journal of Medicine 364 (25), 2381-2391, 2011 | 1147 | 2011 |
| Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell … J Bellmunt, C Théodore, T Demkov, B Komyakov, L Sengelov, ... J Clin Oncol 27 (27), 4454-4461, 2009 | 855 | 2009 |
| Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior … J Bellmunt, H von der Maase, GM Mead, I Skoneczna, M De Santis, ... Journal of Clinical Oncology 30 (10), 1107, 2012 | 507 | 2012 |
| Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 … JB Vermorken, J Stöhlmacher-Williams, I Davidenko, L Licitra, E Winquist, ... The lancet oncology 14 (8), 697-710, 2013 | 493 | 2013 |
| Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Bellmunt, TK Choueiri, R Fougeray, FAB Schutz, Y Salhi, E Winquist, ... Journal of Clinical Oncology 28 (11), 1850-1855, 2010 | 452 | 2010 |
| Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases PTH Tai, E Yu, E Winquist, A Hammond, L Stitt, J Tonita, J Gilchrist Journal of clinical oncology 18 (12), 2493-2499, 2000 | 434 | 2000 |
| Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial AC Nichols, J Theurer, E Prisman, N Read, E Berthelet, E Tran, K Fung, ... The Lancet Oncology 20 (10), 1349-1359, 2019 | 402 | 2019 |
| Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis E Winquist, TS Kirchner, R Segal, J Chin, H Lukka The Journal of urology 171 (2), 561-569, 2004 | 393 | 2004 |
| Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study SJ Hotte, EW Winquist, E Lamont, M MacKenzie, E Vokes, EX Chen, ... Journal of Clinical Oncology 23 (3), 585-590, 2005 | 305 | 2005 |
| Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ... Journal of Clinical Oncology 32 (30), 3436, 2014 | 301 | 2014 |
| Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group MJ Moore, EW Winquist, N Murray, IF Tannock, S Huan, K Bennett, ... Journal of clinical oncology 17 (9), 2876-2876, 1999 | 294 | 1999 |
| Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate … DS Ernst, IF Tannock, EW Winquist, PM Venner, L Reyno, MJ Moore, ... Journal of Clinical Oncology 21 (17), 3335-3342, 2003 | 293 | 2003 |
| Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non–adenoid cystic carcinoma … M Agulnik, EWE Cohen, RB Cohen, EX Chen, EE Vokes, SJ Hotte, ... Journal of Clinical Oncology 25 (25), 3978-3984, 2007 | 286 | 2007 |
| Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma C Elser, LL Siu, E Winquist, M Agulnik, GR Pond, SF Chin, P Francis, ... Journal of Clinical Oncology 25 (24), 3766-3773, 2007 | 285 | 2007 |
| Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group CM Canil, MJ Moore, E Winquist, T Baetz, M Pollak, KN Chi, S Berry, ... Journal of Clinical Oncology 23 (3), 455-460, 2005 | 243 | 2005 |
| Plasma osteopontin: associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma SJ Hotte, EW Winquist, L Stitt, SM Wilson, AF Chambers Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 235 | 2002 |
Sebastien HotteVerified email at execulink.com
